ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Catalent Appoints Lisa Evoli Senior Vice President and Chief Human Resources Officer

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that Lisa Evoli has been named Senior Vice President & Chief Human Resources Officer, effective immediately.

Ms. Evoli joins Catalent from Integra Lifesciences, a global medical technology company based in Princeton, New Jersey.

“Lisa is a proven leader with more than 25 years of experience achieving organizational results, building robust talent pipelines, and creating an inclusive and engaged workforce for a variety of multinational public companies,” said Alessandro Maselli, President and Chief Executive Officer of Catalent. “Her deep health industry knowledge will be highly valuable as we continue to strengthen and support Catalent’s world-class workforce to create value for all our stakeholders.”

Prior to her tenure at Integra Lifesciences, Ms. Evoli held senior leadership roles at TE Connectivity, Johnson & Johnson, and Motorola. She holds a bachelor’s degree in business administration from California University of Pennsylvania and a master’s degree in human resources development from Villanova University.

She will be responsible for leading Catalent’s global human resources strategy, including talent acquisition, leadership development, diversity and inclusion, organizational design, compensation and benefits, HR operations and technology, and performance management.

Ms. Evoli replaces Ricardo Pravda, who will assume the role of Chief Transformation Officer. As part of this new role, Mr. Pravda will assist with the Human Resources aspects of Catalent’s ongoing network portfolio review, which will enable the company to unlock incremental value and require senior executive engagement across the company.

About Catalent, Inc.

Catalent, Inc. (NYSE: CTLT), an S&P 500® company, is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of approximately 18,000 includes more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year. For more information www.catalent.com.

More products. Better treatments. Reliably supplied.™

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.